PA8575501A1 - NEW COMBINATION - Google Patents

NEW COMBINATION

Info

Publication number
PA8575501A1
PA8575501A1 PA20038575501A PA8575501A PA8575501A1 PA 8575501 A1 PA8575501 A1 PA 8575501A1 PA 20038575501 A PA20038575501 A PA 20038575501A PA 8575501 A PA8575501 A PA 8575501A PA 8575501 A1 PA8575501 A1 PA 8575501A1
Authority
PA
Panama
Prior art keywords
new combination
phosphodesterase
antigonist
gmpc
pde5
Prior art date
Application number
PA20038575501A
Other languages
Spanish (es)
Inventor
Bernadette Hughes
David Nathan Abraham Fox
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8575501A1 publication Critical patent/PA8575501A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LAS COMBINACIONES QUE COMPRENDEN A) UN INHIBIDOR DE FOSFODIESTERASA DE TIPO 5 (PDE5) ESPECIFICA DE MONOFOSFATO DE GUANOSINA CICLICO (GMPC) Y B) UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II SON UTILES PARA TRATAR LA HIPERTENSION.THE COMBINATIONS THAT INCLUDE A) A TYPE 5 PHOSPHODESTERASE INHIBITOR (PDE5) SPECIFY OF CYCLIC GUANOSINE MONOPHOSPHATE (GMPC) AND B) AN ANTIGONIST OF THE ANGIOTENSIN II RECEIVER ARE USEFUL TO TREAT HYPERTENSION.

PA20038575501A 2002-06-26 2003-06-13 NEW COMBINATION PA8575501A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination

Publications (1)

Publication Number Publication Date
PA8575501A1 true PA8575501A1 (en) 2003-12-30

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038575501A PA8575501A1 (en) 2002-06-26 2003-06-13 NEW COMBINATION

Country Status (20)

Country Link
EP (1) EP1524996A2 (en)
JP (1) JP2005531627A (en)
KR (1) KR20050013156A (en)
CN (1) CN1662257A (en)
AR (1) AR040337A1 (en)
AU (1) AU2003242895A1 (en)
BR (1) BR0312030A (en)
CA (1) CA2491002A1 (en)
GB (1) GB0214784D0 (en)
GT (1) GT200300124A (en)
MX (1) MXPA04012569A (en)
NO (1) NO20050400L (en)
PA (1) PA8575501A1 (en)
PE (1) PE20040868A1 (en)
PL (1) PL375079A1 (en)
RU (1) RU2004136276A (en)
TW (1) TW200404546A (en)
UY (1) UY27863A1 (en)
WO (1) WO2004002461A2 (en)
ZA (1) ZA200409532B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US7756327B2 (en) * 2002-07-26 2010-07-13 Olympus Corporation Image processing system having multiple imaging modes
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (en) * 2005-03-31 2006-11-28 Univ Minas Gerais process of developing substances as potent and selective inhibitors of phosphodiesterase isoforms of types 1 to 5 (pde1, pde2, pde3, pde4, pde5) based on diocleine, fluranol or analogs and their pharmaceutical compositions for the study and treatment of cardiovascular disease and associated products
RU2369392C2 (en) * 2005-06-10 2009-10-10 Донг-А Фармасьютикал. Ко., Лтд. Pyrazolpyramidinon derivative-containing medicine for liver diseases treatment and prevention
EP1909793A2 (en) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
EP2377530A3 (en) * 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2382975A3 (en) * 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
EP2295436A1 (en) * 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2001276607A1 (en) * 2000-08-11 2002-02-25 Pfizer Inc. Treatment of the insulin resistance syndrome with selective CGMP PDE5 inhibitors

Also Published As

Publication number Publication date
JP2005531627A (en) 2005-10-20
CN1662257A (en) 2005-08-31
PE20040868A1 (en) 2004-11-25
ZA200409532B (en) 2006-06-28
EP1524996A2 (en) 2005-04-27
RU2004136276A (en) 2005-09-10
NO20050400L (en) 2005-03-29
WO2004002461A3 (en) 2004-05-13
CA2491002A1 (en) 2004-01-08
BR0312030A (en) 2005-03-22
TW200404546A (en) 2004-04-01
AU2003242895A1 (en) 2004-01-19
MXPA04012569A (en) 2005-04-19
UY27863A1 (en) 2003-12-31
GB0214784D0 (en) 2002-08-07
GT200300124A (en) 2004-03-17
WO2004002461A2 (en) 2004-01-08
KR20050013156A (en) 2005-02-02
PL375079A1 (en) 2005-11-14
AR040337A1 (en) 2005-03-30

Similar Documents

Publication Publication Date Title
ECSP034519A (en) XANTINA PHOSPHODIESTERASE V INHIBITORS
DE60319364D1 (en) SUBSTITUTED PYRROLINS AS KINASE INHIBITORS
ECSP088543A (en) ANTI-OX40L ANTIBODIES AND METHODS THAT USE THEM
IS6689A (en) Phosphonate-nucleotide analogues and methods used to select and create them
DK1583541T3 (en) Compounds and Methods to Increase Neurogenesis
DK1682530T3 (en) Pyrrole-substituted indoles as inhibitors of PAI-1
HN2003000285A (en) NEW ESPIROCONDENSED QUINAZOLINONES AND ITS USE AS PHOSPHODIESTERASE INHIBITORS
EP1673573A4 (en) Improved light source using light emitting diodes and an improved method of collecting the energy radiating from them
DE60323749D1 (en) SUBSTITUTED PYRROLINS AS KINASE INHIBITORS
EA200602221A1 (en) NEW APPLICATION OF PEPTIDE CONNECTIONS FOR THE TREATMENT OF PAIN IN TRIGEMINAL NEURALGIA
PA8575501A1 (en) NEW COMBINATION
MA29154B1 (en) GEMCITABINE AMIDE PROMEDICAMENT, COMPOSITIONS AND USES THEREOF
PA8574201A1 (en) NEW COMBINATION
AR029838A1 (en) SUBSTITUTED BENZONITROGEN HETEROCICLES
ECSP045466A (en) PEPTIDE-DISFORMILASE INHIBITORS
BR0314196A (en) Tgf-beta inhibitors
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
UY27192A1 (en) PEPTIDE DEFORMILASE INHIBITORS
DE69835288D1 (en) COMBINATION THERAPY FOR MODULATING THE HUMAN SEXUAL REACTION
TW200605885A (en) Multicyclic lonidamine analogs
ATE530982T1 (en) USB DEVICE
NO20032762D0 (en) Activity Management Apparatus
HN2003000071A (en) COMBINATIONS OF A BINDING ALFA-2-DELTA WITH A SELECTIVE INHIBITOR OF THE CYCLOOXYGENASA-2
DE60324418D1 (en) Non-nucleoside inhibitors of the reverse transcriptase
SE0302361D0 (en) Inhibition of uptake of monoamine